Drug Type Small molecule drug |
Synonyms (-)-alpha-Methyl-L-tyrosine, (-)-α-methyl-L-tyrosine, (S)-alpha-Methyltyrosine + [18] |
Target |
Mechanism TYH inhibitors(Tyrosine 3-hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (03 Oct 1979), |
Regulation- |
Molecular FormulaC10H13NO3 |
InChIKeyNHTGHBARYWONDQ-JTQLQIEISA-N |
CAS Registry672-87-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00762 | Metyrosine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pheochromocytoma | US | 03 Oct 1979 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
DiGeorge Syndrome | Phase 2 | US | 01 Jun 2010 | |
Psychotic Disorders | Phase 2 | US | 01 Jun 2010 |
Phase 2 | 2 | (Metyrosine) | wykeisqzpi(eqfhnzsarv) = zihxnmopmc gjftejdnkh (njecqxrxsn, uoqyxuvlrv - oezhuzkflw) View more | - | 08 May 2018 | ||
Placebo (Placebo) | wykeisqzpi(eqfhnzsarv) = pbrgpqfwhp gjftejdnkh (njecqxrxsn, htzfcatyeq - gftzkjvczl) View more |